# US 2003/0229077 A1 · Nitrogen-containing heterocyclic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229077 A1
- Document ID: US20030229077A1
- Status: Published application
- Kind: A1
- Application number: 10/227,302
- Filed: 2002-08-26
- Published: 2003-12-11
- Earliest claimed: 1996-10-01
- Assignees: Millenniumium Pharmaceuticals, Inc.
- Inventors: Kenji Matsuno; Michio Ichimura; Yuji Nomoto; Shigeki Fujiwara; Shinichi Ide; Eiji Tsukuda; Junko Irie; Shoji Oda
- Web page: https://patentgrep.com/patent/US20030229077A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 215/46: with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
- C07D 217/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D 237/34: with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
- C07D 239/94: Nitrogen atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of PDGF receptor to hinder abnormal cell growth and cell wandering and thus are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis. The compounds are represented by general formula (I): 1 wherein V represents an oxygen atom or a sulfur atom; W represents 1,4-piperazinediyl or 1,4-homopiperazinediyl in which carbons on the ring may be substituted by unsubstituted alkyl groups; X represents a nitrogen atom or C—R9; Y represents a nitrogen atom or C—R8; Z represents a nitrogen atom or C—R7 (provided that at least one of X, Y and Z represents a nitrogen atom); R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R2 represents a substituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R3, R4, R5 and R6, which may be the same or different, each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a nitro group, a cyano group, —OR12, —NR15R16, etc.; R7 represents a halogen atom, etc.; R8 has the same significance as R7, and R9 represents a hydrogen atom or —COR41.

## Claims

### Claim 1

A nitrogen-containing heterocyclic compound represented by general formula (I):
576
{wherein
V represents an oxygen atom or a sulfur atom;
W represents 1,4-piperazinediyl or 1,4-homopiperazinediyl in which carbons on the ring may be substituted by 1-4 alkyl groups which may be the same or different;
R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted heteroaryl group, or a substituted or unsubstituted heteroarylalkyl group;
R2 represents a substituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted heteroarylalkyl group, —COR10 (wherein R10 has the same significance as R1) or —SO2R11 (wherein R11 represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted heteroaryl group, or a substituted or unsubstituted heteroarylalkyl group);
R3, R4, R5 and R6, which may be the same or different, each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a nitro group, a cyano group, —OR12 [wherein R12 has the same significance as R10, or represents —COR13 (wherein R13 has the same significance as R10) or —SO2R14 (wherein R14 has the same significance as R11)], —NR15R16 {wherein R15 has the same significance as R10, and R16 has the same significance as R10, or represents —SO2R17 (wherein R17 has the same significance as R11) or
577
[wherein X1 represents an oxygen atom or a sulfur atom; and R18 has the same significance as R10, or represents —OR19 (wherein R19 has the same significance as R11) or —NR20R21 (wherein R20 has the same significance as R10 and R21 has the same significance as R10, or R20 and R21 are combined together with the adjoining nitrogen atom to represent a substituted or unsubstituted nitrogen-containing alicyclic heterocyclic group)]; or R15 and R16 are combined together with the adjoining nitrogen atom to represent a substituted or unsubstituted nitrogen-containing heterocyclic group},
578
[wherein m represents an integer of 0-2; and when m is 0, R22 has the same significance as R10; when m is 1, R22 has the same significance as R11; and when m is 2, R22 has the same significance as R11, or represents —OR23 (wherein R23 has the same significance as R10) or —NR24R25 (wherein R24 and R25, which may be the same or different, each has the same significance as R10, or R24 and R25 are combined together with the adjoining nitrogen atom to represent a substituted or unsubstituted nitrogen-containing alicyclic heterocyclic group)] or —COR26 [wherein R26 has the same significance as R10, or represents —OR27 (wherein R27 has the same significance as R10) or —NR28R29 (wherein R28 and R29, which may be the same or different, each has the same significance as R10, or R28 and R29 are combined together with the adjoining nitrogen atom to represent a substituted or unsubstituted nitrogen-containing alicyclic heterocyclic group)]; or any adjoining two of R3, R4, R5 and R6 are combined together to represent methylenedioxy or ethylenedioxy; or any adjoining two of R3, R4, R5 and R6 are combined together with the two adjoining carbon atoms to form a substituted or unsubstituted phenyl ring; or R3 and R4, R4 and R5, or R5 and R6 are combined together with the two adjoining carbon atoms to represent
579
[wherein A represents an oxygen atom, a sulfur atom or —NR30— (wherein R30 has the same significance as R10); and Q1 has the same significance as R10, or represents —NR31R32 (wherein R31 and R32, which may be the same or different, each has the same significance as R10, or R31 and R32 are combined together with the adjoining nitrogen atom to represent a substituted or unsubstituted nitrogen-containing alicyclic heterocyclic group) or —SR33 (wherein R33 has the same significance as R10)], or
580
(wherein R34 and R35, which may be the same or different, each has the same significance as R10; and Q2 represents an oxygen atom, a sulfur atom or ═N—CN), or
581
(wherein R36 has the same significance as R10);
Z represents a nitrogen atom or C—R7 [wherein R7 has the same significance as R10, or represents a halogen atom, —OR37 (wherein R37 has the same significance as R10), —SR38 (wherein R38 has the same significance as R10) or —NR39R40 (wherein R39 has the same significance as R10 and R40 has the same significance as R10, or R39 and R40 are combined together with the adjoining nitrogen atom to represent a substituted or unsubstituted nitrogen-containing alicyclic heterocyclic group)];
Y represents a nitrogen atom or C—R8 (wherein R8 has the same significance as R7); and
X represents a nitrogen atom or C—R9 [wherein R9 represents a hydrogen atom or —COOR41 (wherein R41 has the same significance as R18)],
provided that at least one of X, Y and Z represents a nitrogen atom},
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein W is 1,4-piperazinediyl, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

A compound according to claim 2, wherein X and Z each represents a nitrogen atom, and Y is CH, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

A compound according to claim 3, wherein R3 and R6 each represents a hydrogen atom, and R4 and R5 each represents a halogen atom, a substituted or unsubstituted alkyl group or OR12, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

A compound according to claim 4, wherein R12 is methyl, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

A compound according to claim 5, wherein R1 represents a hydrogen atom, and R2 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted heteroaryl group or a substituted or unsubstituted heteroarylalkyl group, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

A compound according to claim 6, wherein R2 represents a substituted or unsubstituted aryl group or a heteroaryl group, and V is an oxygen atom, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 6)

A compound according to claim 6, wherein R2 represents a substituted or unsubstituted aralkyl group or a substituted or unsubstituted heteroarylalkyl group, and V is a sulfur atom, or a pharmaceutically acceptable salt thereof.

### Claim 9

A pharmaceutical composition comprising a nitrogen-containing heterocyclic compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
